Billiontoone (NASDAQ:BLLN) Releases Earnings Results, Hits Expectations

Billiontoone (NASDAQ:BLLN) released its quarterly earnings data on Wednesday. The company reported $0.15 earnings per share for the quarter, meeting the consensus estimate of $0.15, FiscalAI reports. Billiontoone had a return on equity of 12.84% and a net margin of 8.04%.The business had revenue of $109.45 million for the quarter.

Here are the key takeaways from Billiontoone’s conference call:

• Q2 revenue rose 64% year over year to $109.4 million, driven by 35% test-volume growth and a 21% increase in average selling price. Oncology revenue surged 176% to $13.7 million, while prenatal revenue increased 56% to $95.8 million.
• Gross margin expanded to 70.5% from 65.3% a year earlier, while the company generated $5.5 million in GAAP operating income, a 15% adjusted EBITDA margin, and $5.1 million of free cash flow. Cash and equivalents ended the quarter at $549 million.
• BillionToOne highlighted several growth catalysts, including strong early adoption of Unity Confirm, the upcoming 130-gene Fetal Risk Screen, Northstar Origin, and a planned tumor-naive MRD launch by year-end. Management also expects the newly completed Epic Aura integration and expanded sales force to support health-system growth over the next two to four quarters.
• A peer-reviewed study supported Northstar Response’s utility in monitoring immunotherapy, and management expects to pursue MolDX Medicare coverage by year-end. Coverage could improve oncology reimbursement and economics, although the company said future MRD growth may temporarily dilute margins.
• The company held more than $10 million in claims pending in-network implementation by national payers, creating uncertainty around the timing and amount of future collections and contributing to lower quarterly true-up revenue. BillionToOne reiterated its 2026 revenue guidance of $450 million to $465 million and is not including additional true-up revenue in that outlook.

Billiontoone Stock Performance

Shares of BLLN stock traded up $1.71 during midday trading on Friday, hitting $93.36. 517,581 shares of the company were exchanged, compared to its average volume of 527,376. Billiontoone has a 52 week low of $61.96 and a 52 week high of $150.44. The firm has a market capitalization of $4.29 billion and a P/E ratio of 133.22. The firm’s 50 day moving average price is $116.61 and its two-hundred day moving average price is $94.28. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92.

Insider Activity at Billiontoone

In other Billiontoone news, insider Shan Riku Sakakibara sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $110.00, for a total transaction of $880,000.00. Following the completion of the sale, the insider directly owned 208,000 shares in the company, valued at $22,880,000. This trade represents a 3.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO David Tsao sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $102.27, for a total value of $2,045,400.00. Following the sale, the chief technology officer owned 1,000 shares of the company’s stock, valued at approximately $102,270. This represents a 95.24% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 202,049 shares of company stock valued at $23,496,861 in the last 90 days. Insiders own 50.22% of the company’s stock.

Institutional Trading of Billiontoone

Institutional investors have recently added to or reduced their stakes in the company. Rossby Financial LCC acquired a new stake in shares of Billiontoone during the fourth quarter worth $25,000. Wells Fargo & Company MN acquired a new position in shares of Billiontoone in the fourth quarter valued at about $76,000. Smartleaf Asset Management LLC acquired a new position in shares of Billiontoone in the fourth quarter valued at about $80,000. Nano Cap New Millennium Growth Fund L P bought a new position in Billiontoone during the fourth quarter worth about $82,000. Finally, Thrive Wealth Management LLC bought a new position in Billiontoone during the second quarter worth about $240,000.

Analyst Ratings Changes

BLLN has been the topic of several research analyst reports. Guggenheim initiated coverage on shares of Billiontoone in a report on Monday, June 29th. They set a “buy” rating and a $125.00 target price on the stock. BTIG Research dropped their price objective on Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Finally, JPMorgan Chase & Co. lowered their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Billiontoone has a consensus rating of “Moderate Buy” and a consensus target price of $126.71.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.